Melbourne, Australia; November 20, and New York, USA; November 19, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), today announced that it has entered into an exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture and commercialization of Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L, with an initial focus on the development of the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.
sorry @Treed and @DeputyDawg , @col69 reposted previous Novartis announcement (above) that I had forgotten, focusing Novartis on Ards. Hands up I’m an idiot, apologies, It will cover any REM-l treatment. Well on Crohn’s, colitis and all inflammatory bowel problems we are going to be huge. Novartis will know that while they wait for the Ards data. Today’s announcement was another poorly handled announcement. Still content with my investment, but I have moved my timeline a bit. I can live with that, but like most want it to happen yesterday.
regards
Yelrom
Cell Therapy News/Articles, page-8781
-
- There are more pages in this discussion • 9,040 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.015(1.29%) |
Mkt cap ! $1.347B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $4.551M | 3.886M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 98246 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 19079 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |